Press Releases

Sign Up For Updates
Date Description View
02/08/18

Denali Therapeutics And Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines
01/05/18

Takeda And Denali Therapeutics Collaborate To Develop And Commercialize Therapies For Neurodegenerative Diseases
12/20/17

Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’s Disease
12/12/17

Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares
12/07/17

Denali Therapeutics Announces Pricing Of Initial Public Offering
08/25/16

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B
09/08/15

Denali Therapeutics Appoints Steve E. Krognes As Chief Financial Officer
07/22/15

Denali Therapeutics Appoints Carole Ho, M.D., As Chief Medical Officer And Head Of Development
05/14/15

Denali Therapeutics Launches With Initial Investment To Discover And Develop Treatments For Neurodegenerative Diseases
Displaying 1-10 of 29 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox

Required fields denoted by an asterisk (*).

Investor & Media Relations